The global pandemic has accelerated the need to modernize clinical trials via a virtual (decentralized) framework. In this educational webinar, the speakers will explore the use of clinical outcome assessments (COAs) for the measurement of endpoints in clinical trials planned to support the approval of new therapeutic agents in the field of neuroscience. The strengths of this framework as well as the challenges and necessary scientific and operational considerations are presented.
Register for this webinar to hear experts from Covance by Labcorp discuss diverse perspectives to enable virtual patient-focused drug development in neuroscience.
Tetyana Korchak, MD, Executive Director, Neuroscience, Ophthalmology and Women’s Health, Clinical Development Solutions, Labcorp Drug Development
Dr. Tetyana Korchak has medical training in ophthalmology, with over 20 years of industry experience at CRO, biotech and investigative site settings across a broad range of therapeutic areas, including but not limited to neuroscience, oncology, ophthalmology and women’s health.
Specific to neuroscience, her expertise encompasses neurodegenerative, acute and rare neurology and various psychiatric diseases. She also has deep experience supporting translational/early phase development through product launch, late-phase/post-marketing studies, encompassing clinical development strategy and planning, program feasibility, risk assessment and execution.
Vanessa Patel, MS, PhD, Director, Patient-Centered Assessment, Labcorp Drug Development
Vanessa Perez Patel, MS, PhD is a formally trained epidemiologist and biostatistician with over 10 years of experience in scientific consulting and the pharmaceutical industry where she has led and implemented global health economic and outcomes research strategies in support of various indications across portfolios largely spanning neuroscience, infectious disease, women’s health and rare disease.
Her expertise in neuroscience encompasses the demonstration of multi-stakeholder value of therapies in development for psychiatric illness and neuro-genetic disorders including conditions associated with cognitive and behavioral issues. She holds advanced degrees in Epidemiology and Biostatistics from the University of Michigan, Ann Arbor, and a degree in Applied Mathematics from the University of California, Los Angeles.
Elan Cohen, PhD, Principal Investigator, Hassman Research Institute
Dr. Elan Cohen is currently a Principal Investigator at Hassman Research Institute (HRI) located in Marlton, NJ where inpatient and outpatient Phase I-IV Healthy Normals, CNS and medically focused clinical trials are conducted. Stemming from his work at HRI as well as his previous role as Director at a rater training vendor and CRO, since 2007 in the clinical trial industry, Dr. Cohen’s experience and expertise has extended to developing and writing clinical trial protocols, rater training, data surveillance, psychiatric scale management and applying such evaluations into clinical trial methodologies, integrating regulatory compliance matters with rater training programs and implementing systemic strategies aimed to reduce the placebo and nocebo effects. Dr. Cohen has presented at Investigators’ Meetings and industry conferences and has been published regarding empirical explorations of placebo and nocebo effect mitigations, namely Dr. Hassman and his proprietary Placebo-Control Reminder Script (PCRS). Dr. Cohen is also a Licensed Psychologist in Pennsylvania and New Jersey.
Who Should Attend?
- Chief Medical Officer
- Chief Executive Officer
- Senior Medical Director
- Medical Director
- Clinical Development Director
- Research and Development Director
- Clinical Outcome Assessment Specialist
- Operational Director
- Senior Operational Director
- Clinical Director
- Senior Clinical Director
- Research Director
- Project Director
- Project Manager
What You Will Learn
In this webinar, participants will learn about:
- Multi-stakeholder benefits of decentralized clinical trials in neuroscience
- Key design and operational considerations for using eCOA
- An overview of best practices
Labcorp Drug Development
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. Learn more about Labcorp at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.